FREQUENTLY ASKED QUESTIONS

VYEPTI is indicated for the preventive treatment of migraine in adults.¹

GET THE FULL PRESCRIBING INFORMATIONSEE THE FULL PATIENT INFORMATION

SEE EFFICACY RESULTS

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.¹

SEE ADDITIONAL IMPORTANT SAFETY INFORMATIONSEE SAFETY DATA 

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.¹

SEE ADDITIONAL IMPORTANT SAFETY INFORMATION SEE SAFETY DATA

Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.¹

SEE ADDITIONAL IMPORTANT SAFETY INFORMATIONSEE SAFETY DATA

Eptinezumab-jjmr is a monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.¹

EXPLORE THE MECHANISM OF ACTION

VYEPTI is the only CGRP antagonist (anti-CGRP) administered by IV every 3 months.¹ It was specifically designed for IV administration and is 100% bioavailable following the 30-minute infusion.²

SEE HOW IT WORKSSEE MORE CLINICAL PHARMACOLOGY INFORMATION

VYEPTI was evaluated for prevention of migraine in 2 randomized, multicenter, double-blind, placebo-controlled studies: PROMISE-1 in 665 patients with episodic migraine over a period of 12 months, and PROMISE-2 in 1072 patients with chronic migraine over a period of 6 months. VYEPTI was administered by IV every 3 months in both studies.¹

REVIEW EPISODIC MIGRAINE STUDY DESIGNREVIEW CHRONIC MIGRAINE STUDY DESIGN

Episodic migraine was defined as 4 to 14 headache days per month, of which ≥4 were migraine days.¹ Chronic migraine was defined as ≥15 to ≤26 headache days per month, of which ≥8 were migraine days.¹ One month was defined as 28 consecutive days.^3,4

RESULTS FOR EPISODIC MIGRAINERESULTS FOR CHRONIC MIGRAINE

• The most common adverse reactions (incidence ≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity
• 1.9% of patients treated with VYEPTI discontinued treatment due to adverse events
• Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice

PROMISE-1 was a parallel-group, double-blind, placebo-controlled global trial to evaluate the efficacy and safety of VYEPTI for the preventive treatment of episodic migraine in adults. A total of 665 patients were randomized and received placebo (n=222), VYEPTI 100 mg (n=221), or VYEPTI 300 mg (n=222) every 3 months for 12 months.⁵

*Calculated by multiplying the mean change from baseline in mean monthly migraine days (MMD) by 3 months.
†p=0.018 vs placebo.
‡Analysis of covariance model used to test for difference between treatment groups.

SEE MORE RESULTS

• The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity
• 1.9% of patients treated with VYEPTI discontinued treatment due to adverse events
• Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice

PROMISE-2 was a parallel-group, double-blind, placebo-controlled global trial to evaluate the efficacy and safety of VYEPTI for the preventive treatment of chronic migraine in adults. A total of 1072 patients were randomized and received placebo (n=366), VYEPTI 100 mg (n=356), or VYEPTI 300 mg (n=350) every 3 months for 6 months.⁴

*Calculated by multiplying the mean change from baseline in mean monthly migraine days (MMD) by 3 months.
†p<0.001 vs placebo.
‡Analysis of covariance model used to test for difference between treatment groups.

SEE MORE RESULTS

VYEPTI is indicated for the preventive treatment of migraine in adults. Every patient has unique needs. Explore the patient profiles¹:

EPISODIC MIGRAINE PATIENT PROFILECHRONIC MIGRAINE PATIENT PROFILE

The recommended dosage is 100 mg administered by IV infusion every 3 months. Some patients may benefit from a dosage of 300 mg administered by IV infusion every 3 months.¹

VYEPTI is for IV infusion only; infuse over approximately 30 minutes. Do not administer VYEPTI as an IV push or bolus injection. Use an IV infusion set with a 0.2 µm or 0.22 µm in-line or add-on sterile filter. After the infusion is complete, flush the line with 20 mL of 0.9% Sodium Chloride Injection, USP. No other medications should be administered through the infusion set or mixed with VYEPTI.¹

For more information on the 300 mg data, please see the Prescribing Information.

EXPLORE THE DOSING AND ADMINISTRATION

VYEPTI is indicated for the preventive treatment of migraine in adults.¹

GET THE FULL PRESCRIBING INFORMATION

VYEPTI can be obtained through a network of specialty distributors and specialty pharmacies. Please call 833-4-VYEPTI, for more information.

LEARN HOW TO ORDER VYEPTI

VYEPTI CONNECT is not mandatory. For enrolled patients, VYEPTI CONNECT offers access and reimbursement information and information about potential financial assistance that may be available for eligible patients. A Field Reimbursement Team is available to help navigate the access process. Please call 833-4-VYEPTI for more information.

LEARN MORE ABOUT VYEPTI CONNECT

Financial assistance is available for eligible commercially insured patients through the VYEPTI Copay Assistance Program. Patients may pay as little as $5 per infusion every 3 months for VYEPTI. A maximum annual benefit limit of $4000 and other restrictions may apply.* Patients can check eligibility requirements and enroll in the program by calling 833-4-VYEPTI, or learn more here.

*Patients are not eligible for financial assistance if they are uninsured or if their prescription is eligible to be reimbursed, in whole or in part, by any state or federal healthcare programs, including but not limited to Medicare or Medicaid, US Department of Veterans Administration, US Department of Defense, or TRICARE. The VYEPTI Copay Assistance Program covers the cost of VYEPTI only. Administration and other fees are not covered by this copay program. Patients must be US residents aged 17 years or older and have a valid VYEPTI prescription. Click here for full Terms and Conditions for the VYEPTI Copay Assistance Program.

VYEPTI GO is a personalized support program designed to help patients through their VYEPTI treatment journey. Eligible patients who have been prescribed VYEPTI can access a range of resources to help them stay on track. Patients can learn more about VYEPTI GO here.

Contact a Lundbeck representative or get in touch with us for questions about VYEPTI, access support, and more. You can contact us by phone at 833-4-VYEPTI.

CONNECT WITH US

SIGN UP TO STAY INFORMED

GET ENROLLMENT INFORMATION

SEE THE OPTIONS